DualityBio Advances HER2 ADC Toward China Approval
SHANGHAI, China, April 9, 2026 DualityBio has announced that the China National Medical Products Administration (NMPA) has accepted the...
phase III trial
Advertisement
GSK Wins China Approval for Exdensur in Severe Asthma
LONDON, UK — March 30, 2026 In a major advancement in respiratory medicine and biologic drug innovation, GSK plc...
GSK Bepirovirsen Wins EMA Review for Hepatitis B Drug
London, UK | March 27, 2026 EMA Accepts First-in-Class Hepatitis B Therapy for Review GSK has announced that the...
Pharming Group Secures Japan Approval for Joenja in APDS
LEIDEN, NETHERLANDS, March 24, 2026 Pharming Group has announced that Japan’s Ministry of Health, Labour and Welfare has approved...
FDA Approves Rhythm Pharmaceuticals’ IMCIVREE for Acquired Hypothalamic Obesity
BOSTON, March 19, 2026 Rhythm Pharmaceuticals announced that the U.S. Food and Drug Administration has approved Imcivree (setmelanotide) for...
Advertisements
Iza-bren Meets Dual Endpoints in Phase III TNBC
REDMOND, Wash. & PRINCETON, N.J., February 26, 2026 SystImmune, Inc. and Bristol Myers Squibb announced positive interim topline results...
Gazyva Phase III Success in Autoimmune Kidney Disease
SOUTH SAN FRANCISCO, Calif., Feb. 16, 2026 — Genentech announced positive Phase III clinical trial results showing that Gazyva®...
Levacetylleucine Phase III Success in A-T Trial
AUSTIN, Texas, Feb. 12, 2026 — IntraBio announced positive topline results from its pivotal Phase III IB1001-303 clinical trial...
Cardiol Raises $13.5M to Advance Late-Stage Heart Drug Trials
Toronto, Ontario, January 16, 2026 — Cardiol Therapeutics announced a bought deal private placement financing for gross proceeds of...
Novartis Fabhalta® Slows Kidney Function Decline in Phase III IgAN Study
BASEL, Oct. 16, 2025 — Novartis announced positive final Phase III results from its APPLAUSE-IgAN trial, confirming that Fabhalta®...
Advertisement
